Related Experiment Video
Updated: May 14, 2026
In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
[Vena cava filter. Which indications remain in the era of differentiated anticoagulation?]
1Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Marburg, Philipps-Universität Marburg, Baldingerstraße, Marburg, Germany. andreas.mahnken@med.uni-marburg.de
Insights
Inferior vena cava (IVC) filters reduce symptomatic pulmonary embolism (PE) but do not improve survival compared to anticoagulation. Retrievable filters are recommended and should be removed once anticoagulation is established.
Area of Science:
- Cardiovascular Medicine
- Interventional Radiology
Context:
- Venous thromboembolism (VTE) is a significant cardiovascular disease with high mortality rates.
- Inferior vena cava (IVC) filters are used in selected VTE patients, with increasing use of retrievable types.
- Guidelines for IVC filter use present controversial recommendations.
Purpose:
- To evaluate the efficacy and clinical practice of IVC filters in managing VTE.
- To compare IVC filters with anticoagulation therapy for VTE.
- To provide recommendations on the current use and future development of IVC filters.
Summary:
- IVC filters significantly reduce symptomatic PE compared to anticoagulation but offer no survival benefit.
- Clinical use of IVC filters varies, influenced by individual interventionalist experience.
- Retrievable IVC filters are preferred, with emphasis on timely removal once safe anticoagulation is achieved.
Impact:
- Informs clinical decision-making regarding IVC filter implantation and management.
- Highlights the need for standardized guidelines and device removal protocols.
- Guides future research and development of novel IVC filter technologies, such as biodegradable and drug-eluting options.
Clinical/Methodical Issue:
Venous thromboembolism (VTE) is the third most common disease of the cardiovascular system. It is associated with a 30-day lethality in the range of 6 % in deep vein thrombosis and 12 % in pulmonary embolism (PE). There are various guidelines with sometimes controversial recommendations regarding the use of inferior vena cava (IVC) filters.
Standard Radiological Methods:
Implantation of IVC filters is a standard therapy in selected patients with an estimated 259,000 filters implanted in 2012.
Methodical Innovations:
Optionally retrievable filters are increasingly being used in clinical routine practice. Future developments will include biodegradable and drug-eluting filters.
Performance:
When compared to anticoagulation as the reference therapy of VTE, IVC filters will significantly reduce the frequency of symptomatic PE; however, there is no advantage in overall survival for either therapy.
Achievements:
Despite different guidelines in clinical routine practice the use of IVC filters appears to depend on the individual clinical experience and assessment of the interventionalist.
Practical Recommendations:
Nowadays retrievable filters should be used although there are relevant differences between the various devices. As a matter of principle all IVC filters should be removed as soon as adequate anticoagulation can be established.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:25Hemodialysis I: Introduction
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...